Kromek Group plc KMK.L · Stock Open Kromek Group plc in new tab
Kromek Group plc Analysis (KMK.L)
Is Kromek Group plc a good investment? Kromek Group plc (KMK.L) is currently trading at 7.85 GBX.
In terms of valuation, the stock trades at a P/E ratio of 4.38. This relatively low multiple may signal that Kromek Group plc is undervalued compared to historical market norms.
Earnings Schedule: Kromek Group plc is expected to release its next earnings report on June 25, 2026. The market consensus estimate for Forward EPS is 0.00.
Investor FAQ
Does Kromek Group plc pay a dividend?
No, it does not currently pay a dividend.
What asset class is Kromek Group plc?
Kromek Group plc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be June 25, 2026. The company currently has a trailing EPS of 0.02.
Company Profile
Kromek Group plc, together with its subsidiaries, develops, manufactures, and sells radiation detection components and bio-detection technology solutions for the advanced imaging, CBRN detection, and biological threat detection markets. It offers civil nuclear radiation detection products, which include gamma radiation and neutron detectors, high-specification, high-resolution devices, components, and software for nuclear detection problems, as well as offers a range of radiation detectors that use cadmium zinc telluride (CZT) or scintillator technology for gamma-ray and neutron detection. The company also provides advanced imaging products, including CZT gamma detectors for SPECT imaging, CZT bone mineral densitometry detectors, D-Matrix gamma ray imager, and photon-counting spectral CT systems. In addition, it offers products and components for the security and defence markets, including UAV radiation mapping drones, alpha beta probes, radiation detectors, gamma and neutron detectors, D5 RIID, backpack with radiation detection, static node, tactical deployment detector charging station, and vehicle mounted radiation detector, as well as a range of gamma spectroscopy software that enables specialized analysis of samples. Further, the company provides CZT imaging research development platforms, such as the DMatrix and the EV3500 scalable x-ray CZT linear array for laboratory and research imaging; and engages in the scientific research and development activities. It sells its products through distributors, OEMs, and direct sales. The company has operations in the United Kingdom, North America, Asia, Europe, and internationally. The company was founded in 2003 and is headquartered in Sedgefield, the United Kingdom.
Community Discussion